BeStock  
Stocks › Biotechnology › NTLA

Intellia Therapeutics NTLA

US equityMarket cap rank #2862BiotechnologyGene Editing
$12.75 +$0.49 (+4.00%)
Pre-market · Oct 6, 4:10 am ET · After hours $12.75 0.00%
Open$12.35
Prev close$12.26
Day range$11.85 – $12.88
Volume4.97M
Market cap$1.79B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership101.7%-2.86 pts vs. prior quarter
Institutions holding385-2 vs. prior quarter
Insider trades (recent)30 buys / 20 sellsNet buying
Short interest33.31% of floatDays to cover 14.1 · as of 15 Sep 2026
Short-sale volume share26.6%5-day average of daily volume

Short-sale volume as % of daily volume

15%21%26%32%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$6.13M (8 inflow days, 12 outflow days).

The five largest holders on file together own 39.8% of shares outstanding.

Largest holders

  • ARK Investment Management LLC12.04%
  • BlackRock11.00%
  • State Street Global Advisors6.59%
  • Vanguard Portfolio Management, LLC5.23%
  • Vanguard Capital Management, LLC4.96%
  • D. E. Shaw & Co., L.P.4.60%
  • Two Sigma Investments, LP3.74%
  • FMR3.40%

By investor type

  • Mutual Fund70.74%
  • Hedge Fund16.94%
  • Public Company7.17%
  • VC/PE Fund3.55%
  • Private Company2.69%
  • Individual/Insider1.62%
  • Government Pension Fund0.45%
  • Family Office/Trust0.13%

Reported short interest has fallen from 35.23% to 33.31% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 46,681,609 33.3% 14.1
31 Aug 2026 43,928,014 31.3% 12.9
14 Aug 2026 44,880,339 32.0% 13.2
31 Jul 2026 44,010,769 31.5% 12.0
15 Jul 2026 45,776,294 32.8% 9.8
30 Jun 2026 49,218,272 35.2% 7.5

Discussion

No comments yet — be the first to weigh in on NTLA.

Leave a comment

Scroll to Top